Are endocan plasma levels altered in preeclampsia?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | https://doi.org/10.1055/s-0041-1728661 http://hdl.handle.net/1843/57395 |
Resumo: | Our research group has been studying preeclampsia (PE) for over a decade aiming to detect possible blood biomarkers of hemostasis, inflammation, and endothelial dysfunction that could be useful for the diagnosis of PE. Until today, only the onset of hypertension (≥ 140 mmHg systolic or ≥ 90 mmHg diastolic) on or after 20 weeks of gestation in association or not with proteinuria and/or evidences of multisystem impairment (such as renal, liver and neurological dysfunctions) is an acceptable criterion to establish the diagnosis of this gestational disease. It is important to emphasize that PE affects between 2 and 8% of all pregnancies worldwide, an early diagnosis of the disease, before the occurrence of systematic impairment, is still not available, which motivates our arduous search for laboratory markers of PE. Endocan is a biochemical marker of endothelial dysfunction that is potentially associated with immunoinflammatory response. Previous data of our group showed that endothelial dysfunction and inflammation are important features in PE. Aiming to determine if endocan plasma levels could be useful for determining PE predisposition and/or development, we investigate its levels in preeclamptic and normotensive pregnant women from the southeastern state of Minas Gerais, Brazil. |
id |
UFMG_b8b82697439bd74e98de0c7810db294c |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/57395 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2023-08-03T11:56:03Z2023-08-03T11:56:03Z2021-03433232234https://doi.org/10.1055/s-0041-17286610100-7203http://hdl.handle.net/1843/57395Our research group has been studying preeclampsia (PE) for over a decade aiming to detect possible blood biomarkers of hemostasis, inflammation, and endothelial dysfunction that could be useful for the diagnosis of PE. Until today, only the onset of hypertension (≥ 140 mmHg systolic or ≥ 90 mmHg diastolic) on or after 20 weeks of gestation in association or not with proteinuria and/or evidences of multisystem impairment (such as renal, liver and neurological dysfunctions) is an acceptable criterion to establish the diagnosis of this gestational disease. It is important to emphasize that PE affects between 2 and 8% of all pregnancies worldwide, an early diagnosis of the disease, before the occurrence of systematic impairment, is still not available, which motivates our arduous search for laboratory markers of PE. Endocan is a biochemical marker of endothelial dysfunction that is potentially associated with immunoinflammatory response. Previous data of our group showed that endothelial dysfunction and inflammation are important features in PE. Aiming to determine if endocan plasma levels could be useful for determining PE predisposition and/or development, we investigate its levels in preeclamptic and normotensive pregnant women from the southeastern state of Minas Gerais, Brazil.Nosso grupo de pesquisa estuda a pré-eclâmpsia (PE) há mais de uma década com o objetivo de detectar possíveis biomarcadores sanguíneos de hemostasia, inflamação e disfunção endotelial que possam ser úteis para o diagnóstico de PE. Até hoje, apenas o aparecimento de hipertensão (≥ 140 mmHg sistólica ou ≥ 90 mmHg diastólica) em ou após 20 semanas de gestação em associação ou não com proteinúria e/ou evidências de comprometimento multissistêmico (como disfunção renal, hepática e neurológica) é considerado um critério aceitável para estabelecer o diagnóstico desta doença gestacional. É importante ressaltar que a PE afeta entre 2 e 8% de todas as gestações no mundo, ainda não existe um diagnóstico precoce da doença, antes da ocorrência de comprometimento sistemático, o que motiva nossa árdua busca por marcadores laboratoriais de PE. Endocan é um marcador bioquímico de disfunção endotelial que está potencialmente associado à resposta imunoinflamatória. Dados anteriores do nosso grupo mostraram que a disfunção endotelial e a inflamação são características importantes na EP. Com o objetivo de determinar se os níveis plasmáticos de endocan podem ser úteis para determinar a predisposição e/ou desenvolvimento de PE, investigamos seus níveis em gestantes normotensas e com pré-eclâmpsia do estado de Minas Gerais, Brasil.CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas GeraisengUniversidade Federal de Minas GeraisUFMGBrasilFAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICASRevista Brasileira de Ginecologia e ObstetríciaGravidezPré-eclâmpsiaProteoglicanasBiomarcadoresEstudos de casos e controlesHumansFemalePregnancyPre-eclampsiaProteoglycansBiomarkersCase-control studiesAre endocan plasma levels altered in preeclampsia?info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0041-1728661Ana Cristina dos Santos LopesSuellen Rodrigues MartinsLuci Maria SantAna DusseMelina de Barros PinheiroPatrícia Nessralla Alpoimapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/57395/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALAre endocan plasma levels altered in preeclampsia.pdfAre endocan plasma levels altered in preeclampsia.pdfapplication/pdf242049https://repositorio.ufmg.br/bitstream/1843/57395/2/Are%20endocan%20plasma%20levels%20altered%20in%20preeclampsia.pdfaaaa73fa428b99bb65611d0295ec8f7bMD521843/573952023-08-03 13:17:33.143oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-08-03T16:17:33Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
Are endocan plasma levels altered in preeclampsia? |
title |
Are endocan plasma levels altered in preeclampsia? |
spellingShingle |
Are endocan plasma levels altered in preeclampsia? Ana Cristina dos Santos Lopes Humans Female Pregnancy Pre-eclampsia Proteoglycans Biomarkers Case-control studies Gravidez Pré-eclâmpsia Proteoglicanas Biomarcadores Estudos de casos e controles |
title_short |
Are endocan plasma levels altered in preeclampsia? |
title_full |
Are endocan plasma levels altered in preeclampsia? |
title_fullStr |
Are endocan plasma levels altered in preeclampsia? |
title_full_unstemmed |
Are endocan plasma levels altered in preeclampsia? |
title_sort |
Are endocan plasma levels altered in preeclampsia? |
author |
Ana Cristina dos Santos Lopes |
author_facet |
Ana Cristina dos Santos Lopes Suellen Rodrigues Martins Luci Maria SantAna Dusse Melina de Barros Pinheiro Patrícia Nessralla Alpoim |
author_role |
author |
author2 |
Suellen Rodrigues Martins Luci Maria SantAna Dusse Melina de Barros Pinheiro Patrícia Nessralla Alpoim |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Ana Cristina dos Santos Lopes Suellen Rodrigues Martins Luci Maria SantAna Dusse Melina de Barros Pinheiro Patrícia Nessralla Alpoim |
dc.subject.por.fl_str_mv |
Humans Female Pregnancy Pre-eclampsia Proteoglycans Biomarkers Case-control studies |
topic |
Humans Female Pregnancy Pre-eclampsia Proteoglycans Biomarkers Case-control studies Gravidez Pré-eclâmpsia Proteoglicanas Biomarcadores Estudos de casos e controles |
dc.subject.other.pt_BR.fl_str_mv |
Gravidez Pré-eclâmpsia Proteoglicanas Biomarcadores Estudos de casos e controles |
description |
Our research group has been studying preeclampsia (PE) for over a decade aiming to detect possible blood biomarkers of hemostasis, inflammation, and endothelial dysfunction that could be useful for the diagnosis of PE. Until today, only the onset of hypertension (≥ 140 mmHg systolic or ≥ 90 mmHg diastolic) on or after 20 weeks of gestation in association or not with proteinuria and/or evidences of multisystem impairment (such as renal, liver and neurological dysfunctions) is an acceptable criterion to establish the diagnosis of this gestational disease. It is important to emphasize that PE affects between 2 and 8% of all pregnancies worldwide, an early diagnosis of the disease, before the occurrence of systematic impairment, is still not available, which motivates our arduous search for laboratory markers of PE. Endocan is a biochemical marker of endothelial dysfunction that is potentially associated with immunoinflammatory response. Previous data of our group showed that endothelial dysfunction and inflammation are important features in PE. Aiming to determine if endocan plasma levels could be useful for determining PE predisposition and/or development, we investigate its levels in preeclamptic and normotensive pregnant women from the southeastern state of Minas Gerais, Brazil. |
publishDate |
2021 |
dc.date.issued.fl_str_mv |
2021-03 |
dc.date.accessioned.fl_str_mv |
2023-08-03T11:56:03Z |
dc.date.available.fl_str_mv |
2023-08-03T11:56:03Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/57395 |
dc.identifier.doi.pt_BR.fl_str_mv |
https://doi.org/10.1055/s-0041-1728661 |
dc.identifier.issn.pt_BR.fl_str_mv |
0100-7203 |
url |
https://doi.org/10.1055/s-0041-1728661 http://hdl.handle.net/1843/57395 |
identifier_str_mv |
0100-7203 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Revista Brasileira de Ginecologia e Obstetrícia |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
FAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/57395/1/License.txt https://repositorio.ufmg.br/bitstream/1843/57395/2/Are%20endocan%20plasma%20levels%20altered%20in%20preeclampsia.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 aaaa73fa428b99bb65611d0295ec8f7b |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1803589388241731584 |